GGrantIndex
← Search

Analytical Cytometry

$46,391P30FY2025CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

Abstract Shared Resource 01: Analytical Cytometry (AC-SR) To advance our understanding of cancer etiology and to develop improved therapeutic approaches, it is critical for researchers to have the ability to routinely analyze and isolate discrete cell types from complex heterogeneous populations. The Analytical Cytometry Shared Resource (AC-SR) fulfills this vital function for COHCCC Members by providing services to define and isolate discrete immune system cells and cancer cells based on extracellular and intracellular protein expression, to quantify and isolate cells that express fluorescent markers, and to examine discrete cell growth states. Specific Aims for AC-SR: Aim 1. Support flow cytometry experiments for the analysis of cells and small particles. Aim 2. Maintain instrumentation for cell sorting and perform multiparameter sorting. Aim 3. Provide training support for researchers to perform independent flow cytometry analysis and sorting within the AC-SR. The AC-SR provides flow cytometry analysis and sorting instrumentation (18 analyzers, seven sorters) to support the research goals of COHCCC. The AC-SR maintains analysis instruments (7-BD LSRII/Fortessa, Cytek Aurora, BD-Symphony, 3-ThermoFisher Attune NxT, 2-ACEA Quanteons, 1-ACEA Novocyte, 2-BD C6, and BC CyAn) that enable varying degrees of parameter detection for all COH sites. A mass cytometer, Fluidigm CyTOF- Helios, and a small particle analyzer (e.g., exosome and nanoparticle; NanoSight NS300) is also available. Notably, the Aurora, Symphony, and CyTOF instruments are new since the last funding cycle. These instruments allow for high parameter experiments, enabling highly detailed analysis and interrogation of cancer cells, cancer microenvironments, and immunological responses. All analysis instruments can be operated either by researchers or by SR staff. Six cell sorting instruments (BD Aria sorters) are located across COH sites of which 4 are available for self-operation by the trained end user. COHCCC has recently purchased an additional closed system cell sorter (Miltenyi Tyto) to assist with sorting of CAR-T cell products and oncolytic viral research needs. The SR is directed by Dr. Jeremy Stark, a Professor in the Department of Cancer Genetics and Epigenetics and supported by highly qualified staff that maintain and operate the equipment while also providing training to COHCCC researchers who wish to operate AC-SR instruments independently. Members Utilization by %Revenue 2017–21: 93.6 Total (20 MCBC, 4.1 DCT, 24 CI, 45 HM, 0.26 CCPS) Publications by Members: 172, 95 with Impact Factor >10 Grants Supported: 169Total (4 ACS, 12 CIRM, 8 DoD, 6 LLS, 18 NCI of 32NIH (1P01, 88R01, 5U01))

View original record on NIH RePORTER →